Skip to main content

Advertisement

SpringerLink
Log in

Is it time for oncologists to modify their laissez-faire attitude toward alternative/ complementary ‘drug therapy’?

  • Editor’s Commentary
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Burstein HJ, Gelber S, Guadagnoli E, et al.: Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999, 340:1733–1739.

    Article  PubMed  CAS  Google Scholar 

  2. Lippert MC, McClain R, Boyd JC, et al.: Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 1999, 86:2642–2648.

    Article  PubMed  CAS  Google Scholar 

  3. Risberg T, Lund E, Wist E, et al.: Cancer patients use of nonproven therapy: a 5-year follow-up study. J Clin Oncol 1998, 16:6–12.

    PubMed  CAS  Google Scholar 

  4. Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998, 83:777–782.

    Article  PubMed  CAS  Google Scholar 

  5. Fernandez CV, Stutzer CA, MacWilliam L, et al.: Alternative and complementary therapy use in pediatric oncology patients in British Columbia: prevalence and reasons for use and nonuse. J Clin Oncol 1998, 16:1279–1286.

    PubMed  CAS  Google Scholar 

  6. Metz JM, Jones H, Devine P, et al.: Cancer patients use unconventional medical therapies far more frequently than standard history and physical examination suggest. Cancer J 2001, 7:149–154.

    PubMed  CAS  Google Scholar 

  7. Richardson MA, Sanders T, Palmer JL, et al.: Complementary/ alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000, 18:2505–2514.

    PubMed  CAS  Google Scholar 

  8. Boon H, Stewart M, Kennard MA, et al.: Use of complementary/ alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 2000, 18:2515–2521.

    PubMed  CAS  Google Scholar 

  9. Ruschitzka F, Meier PJ, Turina M, et al.: Acute heart transplant rejection due to Saint John’s wort. Lancet 2000, 355:548–549.

    Article  PubMed  CAS  Google Scholar 

  10. Piscitelli SC, Burstein AH, Chaitt D, et al.: Indinavir concentrations and St John’s wort. Lancet 2000, 355:547–548.

    Article  PubMed  CAS  Google Scholar 

  11. Mathijssen RHJ, Verweij J, De Bruijn P, et al.: Modulation of irinotecan (CPT-11) metabolism by St. John’s wort in cancer patients [abstract]. Proc Am Assoc Cancer Res 2002, 43:492.

    Google Scholar 

  12. Bonham MJ, Galkin A, Montgomery B, et al.: Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition. J Natl Cancer Inst 2002, 94:1641–1647.

    PubMed  CAS  Google Scholar 

  13. Jatoi A, Dakhil S, Burch P, et al.: A phase II trial of green tea for androgen-independent prostate cancer: a North Central Cancer Treatment Group (NCCTG) trial [abstract]. Proc Am Assoc Cancer Res 2002, 43:492.

    Google Scholar 

  14. Parker MG: Shark cartilage-induced hepatitis. Ann Intern Med 1996, 125:780–781.

    Google Scholar 

  15. Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 1998, 16:3649–3655.

    PubMed  CAS  Google Scholar 

  16. Hainer MI, Tsai N, Komura ST, Chiu CL: Fatal hepatorenal failure associated with hydrazine sulfate. Ann Intern Med 2000, 133:877–880.

    PubMed  CAS  Google Scholar 

  17. Moertel CG, Fleming TR, Rubin J, et al.: A clinical trial of amygdalin (laetrile) in the treatment of human cancer. N Engl J Med 1982, 306:201–206.

    Article  PubMed  CAS  Google Scholar 

  18. Nortier JL, Martinez M-CM, Schmeiser HH, et al.: Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000, 342:1686–1692.

    Article  PubMed  CAS  Google Scholar 

  19. Lord GM, Cook T, Arlt VM, et al.: Urothelial malignant disease and Chinese herbal nephropathy. Lancet 2001, 358:1515–1516.

    Article  PubMed  CAS  Google Scholar 

  20. Grossman L: The curious case of kava: Why did it take the FDA so long to finally sound the alarm? Time 2002, April 8, p 58.

  21. Ernst E: The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John’s wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med 2002, 136:42–53.

    PubMed  Google Scholar 

  22. White J: PC-SPES: a lesson for future dietary supplement research. J Natl Cancer Inst 2002, 94:1261–1262.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, 44195, Cleveland, OH, USA

    Maurie Markman MD

Authors
  1. Maurie Markman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. Is it time for oncologists to modify their laissez-faire attitude toward alternative/ complementary ‘drug therapy’?. Curr Oncol Rep 6, 1–2 (2004). https://doi.org/10.1007/s11912-996-0001-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-996-0001-0

Search

Navigation